NASDAQ:IMRN
Immuron Limited Stock News
$2.32
+0.0200 (+0.87%)
At Close: May 17, 2024
IMRN Stock Alert: What Is the Huge Catalyst Sending Immuron Soaring?
02:58pm, Wednesday, 12'th Jan 2022
Today marks one of the best days for IMRN stock in a long time, with shares surging nearly 50% on the back of some impressive news. The post IMRN Stock Alert: What Is the Huge Catalyst Sending Immuron
Immuron Shares Rally On US Department Of Defense Funding Of A$6.2M
01:22pm, Wednesday, 12'th Jan 2022 Benzinga
Immuron Limited (NASDAQ: Full story available on Benzinga.com
Here is why Immuron is up 30% on Wednesday
12:52pm, Wednesday, 12'th Jan 2022
Immuron Limited (NASDAQ: IMRN) went up 30% after it announced that it had received $6.2 million from the Department of Defense to conduct clinical research on a dosing regimen for Travelan. This ne
Immuron stock rockets after funding by U.S. DoD of new research agreement
11:34am, Wednesday, 12'th Jan 2022 MarketWatch
Shares of Immuron Ltd. rocketed 49.6% in active premarket trading Wednesday, after the Australia-based biopharmaceutical company said it received an award of AUD$6.2 million ($4.5 million) from the U.S. Department of Defense to evaluate Travelan for military use. Trading volume spiked to 1.3 million shares, compared with the full-day average of about 60,500. The award is aimed at testing the efficacy of a single larger dose regimen of Travelan for the treatment of moderate to severe diarrhea upon challenge with enterotoxigenic Escherichia coli (ETEC). "This new project expands our clinical development program and represents the first of several significant clinical trials which the Company expects to undertake with the US Military in 2022," said Immuron Chief Executive JErry Kanellos. "The new funding is testament to the value proposition our hyperimmune bovine polyclonal colostrum technology offers to benefit the US Military as well as the civilian international travelling population.
Immuron jumps 45% after receiving A$6.2M award from U.S. DoD for Travelan
11:17am, Wednesday, 12'th Jan 2022 Seeking Alpha
Immuron (IMRN) soars 44.9% premarket after announcing the funding of a new research agreement with the U.S Department of Defense (DoD).IMRN is awarded A$4.8M ($3.43M) funding
Immuron Shares Rally On US Department Of Defense Funding Of A$6.2M
08:22am, Wednesday, 12'th Jan 2022
Immuron Limited (NASDAQ: IMRN) has received funding of A$6.2 ($4.45) million from the U.S Department of Defense to examine a dosing regimen for Travelan more suited for use by the military. The Com
Immuron Stock (IMRN): Why The Price Surged Today
07:15am, Wednesday, 12'th Jan 2022
The stock price of Immuron (NASDAQ: IMRN) increased by over 80% pre-market today. This is why it happened.
Immuron stock rockets after funding by U.S. DoD of new research agreement
06:34am, Wednesday, 12'th Jan 2022
Shares of Immuron Ltd. IMRN, +2.67% rocketed 49.6% in active premarket trading Wednesday, after the Australia-based biopharmaceutical company said it received an award of AUD$6.2 million ($4.5 million
Immuron's IMM-124E Shows Antiviral T-Cell Immunity, Potential For COVID-19
08:10am, Friday, 08'th Oct 2021
Immuron Limited (NASDAQ: IMRN) has announced a recent publication of antiviral data from the IMM-124E preclinical and Phase 1/2a trials. The studies were conducted independently by the Hadassah Med
IMM-124E – Demonstrates Antiviral T-Cell Immunity
06:00am, Friday, 08'th Oct 2021
Key Points
Immuron Director resignation
11:00pm, Thursday, 23'rd Sep 2021
MELBOURNE, Australia, Sept. 24, 2021 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian biopharmaceutical company focused on developing and commercializing oral immunotherapeu
Immuron planned Acquisition of R&D Vaccine Company
09:00am, Thursday, 23'rd Sep 2021
MELBOURNE, Australia, Sept. 23, 2021 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian biopharmaceutical company focused on developing and commercializing oral immunotherapeu
IMM124E – May offer a New modality for Inhibition of SARS-CoV-2
06:00am, Thursday, 13'th May 2021
Key Points
Immuron to Participate in H.C. Wainwright & Co. BioConnect 2021 Virtual Conference
06:00am, Monday, 11'th Jan 2021
MELBOURNE, Australia, Jan. 11, 2021 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian biopharmaceutical company focused on developing and commercialising oral immunotherapeut
Immuron SARS-CoV-2 Research Agreement with Monash University
06:00am, Tuesday, 15'th Dec 2020
Key Points